Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia

The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate. The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.

Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Kriya Therapeutics, Inc.Updated: Jun 8, 2026Locations: 1
Eligibility criteria

Participant is capable of providing signed informed consent. [+6]

Participant has bilateral TN pain attacks. [+3]

Read more
Status: Recruiting

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).

Participants needed: 62
Trial details
Phase: Phase 1, Phase 2Age: 55-80Biological sex: AllType: InterventionalSponsor: Kriya Therapeutics, Inc.Updated: Apr 30, 2026Locations: 3
Eligibility criteria

Participant must be between 55 to 80 years of age (inclusive), at the time of si... [+6]

Any ocular disease or condition that is not GA secondary to AMD: Macular atrophy... [+12]

Read more
Status: Not yet recruiting

A Study of VV-14305 for the Treatment of Thyroid Eye Disease

The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).

Participants needed: 110
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Kriya Therapeutics, Inc.Updated: Feb 11, 2026Locations: 1
Eligibility criteria

Must be 18 to 80 years of age (inclusive) at Screening. [+6]

History of serious ocular condition(s) other than TED, including but not limited... [+8]

Read more